Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

482
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
482
Renal Corpuscle01:20

Renal Corpuscle

7.5K
The glomerulus and Bowman's capsule are two essential components of the nephron, which is the functional unit of the kidney. These microscopic structures play a critical role in the process of blood filtration to produce urine.
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
7.5K
Renal Clearance01:23

Renal Clearance

2.7K
The glomerular filtration rate (GFR) is a critical marker of kidney function, reflecting the efficiency of filtration by the glomeruli. Renal clearance of specific substances, such as inulin or creatinine, is commonly used to measure GFR.
Renal clearance refers to the volume of plasma cleared of a specific substance, such as creatinine, per unit of time. To measure clearance, urine samples are collected over a 24-hour period during each bladder voiding, followed by a single blood sample at the...
2.7K
Renal Drug Clearance: Comparison Between Renal Excretion Methods01:08

Renal Drug Clearance: Comparison Between Renal Excretion Methods

620
Renal clearance is a critical parameter encompassing kidney filtration, secretion, and reabsorption processes. It is calculated using a specific equation to determine the rate at which the kidneys clear a drug.
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...
620
Drug Elimination: Non-Renal Routes01:23

Drug Elimination: Non-Renal Routes

3.3K
The liver plays a pivotal role in eliminating drugs and their metabolites, primarily through a process known as biliary excretion. This process involves the hepatocytes, the primary cells in the liver that generate bile. A range of transporters actively expels polar drugs or hydrophilic drug metabolites into the bile, which transports the drugs and metabolites into the small intestine. From here, they are eventually expelled from the body through feces. In some instances, the original drug or a...
3.3K
Renal Tubule and Collecting Duct01:24

Renal Tubule and Collecting Duct

3.6K
The renal tubule is divided into three parts: the proximal convoluted tubule (PCT), the Loop of Henle (LOH), and the distal convoluted tubule (DCT).
Proximal Convoluted Tubule (PCT):
The PCT is the initial segment of the renal tubule, extending from the Bowman's capsule that encloses the glomerulus. Its convoluted structure and microvilli-lined cells increase the surface area for reabsorption. The PCT reabsorbs glucose, amino acids, sodium, and water from the filtrate, ensuring essential...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitochondrial potential reflects T cell fitness and function during cancer immunotherapy.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

Pharmacologic and Oncohistone Inhibition of SETD2 Converge on Genomic Instability.

Cancers·2026
Same author

Flipping the narrative on launching a rewarding career in academic medicine.

Nature cancer·2025
Same author

Targeted Metabolomic Methods for <sup>13</sup>C Stable Isotope Labeling with Uniformly Labeled Glucose and Glutamine Using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).

Journal of proteome research·2025
Same author

A SETD2-CDK1-lamin axis maintains nuclear morphology and genome stability.

Nature cell biology·2025
Same author

Vaccines in cancer treatment and prevention: the time is now.

The Journal of clinical investigation·2025

Related Experiment Video

Updated: Feb 10, 2026

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

9.5K

Renal cell carcinoma.

W Kimryn Rathmell1, Paul A Godley

  • 1Division of Hematology/Oncology, University of North Carolina at Chapel Hill, and the Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599, USA.

Current Opinion in Oncology
|April 8, 2004
PubMed
Summary

New targeted therapies show promise for renal cell carcinoma (RCC). While current treatments like interleukin-2 have limited long-term benefits, advances in surgery and new agents offer hope for patients with this devastating cancer.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.2K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.2K

Related Experiment Videos

Last Updated: Feb 10, 2026

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

9.5K
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.2K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Nephrology

Background:

  • Renal cell carcinoma (RCC) remains a significant health challenge with limited effective treatments.
  • Recent breakthroughs in understanding RCC molecular biology, especially clear cell RCC, are driving new therapeutic strategies.
  • Targeting the hypoxic response pathway is a key focus in developing novel RCC treatments.

Purpose of the Study:

  • To review current and emerging treatment options for renal cell carcinoma.
  • To highlight advancements in surgical techniques and systemic therapies for RCC.
  • To discuss the potential of novel targeted therapies for improving patient outcomes in RCC.

Main Methods:

  • Review of current literature on renal cell carcinoma treatment.
  • Analysis of recent clinical findings in systemic therapies and surgical approaches.
  • Evaluation of emerging targeted agents and their mechanisms of action.

Main Results:

  • High-dose interleukin-2 offers limited long-term benefits for metastatic RCC.
  • Minimally invasive surgical techniques have improved patient care.
  • Systemic advances include bevacizumab (anti-VEGF therapy) and small molecule inhibitors targeting angiogenesis.

Conclusions:

  • Progress in surgical techniques and supportive care is enhancing RCC patient management.
  • Promising targeted therapies are on the horizon for renal cell carcinoma treatment.
  • New therapeutic strategies offer hope for improved outcomes in patients with RCC.